Meta-analysis of 14 studies showed that APS combination therapy significantly increased CD8+ T-cell proportions in tumor tissue (SMD = 3.17, 95% CI [1.00, 5.33], p = 0.004), spleen (SMD = 1.84, 95% CI [0.75, 2.94], p = 0.001) and draining lymph nodes (SMD = 1.36, 95% CI [0.23, 2.49], p = 0.02), respectively. The gene discussed is CD8A; the disease is neoplasm.